Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13857896 | 0.81 | HTR2A (0.61) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL28075653 | 0.80 | TP53 (0.48) | — | |
| SCHEMBL5862483 | 0.79 | HTR2A (0.54) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL121871 | 0.77 | HTR2A (0.50) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL4686356 | 0.77 | GAA (0.43) | — | |
| SCHEMBL27999639 | 0.76 | TTR (0.58) | — | |
| SCHEMBL364754 | 0.75 | SLC6A4 (0.64) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL13860469 | 0.75 | HSD17B10 (0.54) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL17050487 | 0.75 | SLC6A4 (0.49) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL31277237 | 0.74 | CA2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9572811-B2 | Treatment of dry eye | PRINCIPIA BIOPHARMA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| CN-103717602-B | Kinase inhibitors | 加利福尼亚大学董事会 | 2016-11-09 | — | — | CN | disclosed |
| EP-2710005-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| CN-103534258-B | Tyrosine kinase inhibitor | 普林斯匹亚生物制药公司 | 2016-09-14 | — | — | CN | disclosed |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2710005-A1 | TYROSINE KINASE INHIBITORS | Principia Biopharma Inc. (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014022569-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2013191965-A1 | REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES | PRINCIPIA BIOPHARMA INC. (US) | 2013-12-27 | — | — | WO | disclosed |
| WO-2012158764-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158795-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | HTR2A 3214/4885SLC6A4 1273/4885KCNH2 4680/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | HTR2A 3214/4885SLC6A4 1273/4885KCNH2 4680/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | HTR2A 3610/4885SLC6A4 3846/4885KCNH2 4362/4885 |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | HTR2A 1278/4885SLC6A4 1053/4885KCNH2 4318/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | HTR2A 1278/4885SLC6A4 1053/4885KCNH2 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.